Executive Summary
Autonomix Medical (AMIX) reported QQ4 2025 results with no reported revenue across the latest four-quarter window, underscoring the company’s continued status as a development-stage medical device company focused on peripheral nervous system sensing technologies. In the quarter, R&D and G&A expenses combined totaled $3.252 million, driving an EBITDA of -$3.097 million and a net loss of -$3.191 million. Diluted earnings per share stood at -$1.81 on 1.766 million weighted-average shares. While the company remains far from profitability, the YoY metric movements show a mixed profitability signal: operating income declined by 34.6% year-over-year and by 18.4% quarter-over-quarter, whereas net income appeared to improve year-over-year by roughly 41% but declined about 18% sequentially. The absence of revenue and the sizable burn reinforces the need for external funding or strategic milestones (regulatory approvals, clinical data readouts, or partnerships) to extend the company’s runway.
Looking ahead, Autonomix’s trajectory hinges on securing pivotal product and regulatory milestones, potential licensing deals, or collaborations that could monetize its catheter-based microchip-enabled sensing platform. In the near term, investors should monitor liquidity runway, any new capital raising plans, and any updates to product development timelines or clinical validation outcomes. Given the pre-revenue status and concentrated R&D intensity, the stock remains high-risk and highly sensitive to capital market conditions and regulatory progress.
Key Performance Indicators
QoQ: -18.38% | YoY:-34.60%
QoQ: -17.66% | YoY:40.99%
QoQ: -23.97% | YoY:-524.14%
Key Insights
Revenue: N/A; Gross Profit: N/A;
Operating Income: -$3.252 million; YoY: -34.60%; QoQ: -18.38%;
Net Income: -$3.191 million; YoY: +40.99%; QoQ: -17.66%;
EBITDA: -$3.097 million;
EPS (Diluted): -$1.81; YoY: -524.14%; QoQ: -23.97%;
R&D Expenses: $1.553 million;
General and Administrative Expenses: $1.699 million;
Interest Expense: $46,000;
Depreciation & Amortization: $48,000;
Weighted Average Shares Outstanding: 1,766,425....
Financial Highlights
Revenue: N/A; Gross Profit: N/A;
Operating Income: -$3.252 million; YoY: -34.60%; QoQ: -18.38%;
Net Income: -$3.191 million; YoY: +40.99%; QoQ: -17.66%;
EBITDA: -$3.097 million;
EPS (Diluted): -$1.81; YoY: -524.14%; QoQ: -23.97%;
R&D Expenses: $1.553 million;
General and Administrative Expenses: $1.699 million;
Interest Expense: $46,000;
Depreciation & Amortization: $48,000;
Weighted Average Shares Outstanding: 1,766,425.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Operating Income |
-3.25M |
-34.60% |
-18.38% |
| Net Income |
-3.19M |
40.99% |
-17.66% |
| EPS |
-1.81 |
-524.14% |
-23.97% |
Management Commentary
No earnings call transcript data was provided with the input. As a result, there are no management quotes or thematic highlights to extract. If a transcript becomes available, we can add quote-based insights under themes such as strategy, operations, and market conditions.
Forward Guidance
No formal forward guidance was disclosed in the provided data. Given AMIX’s development-stage profile and lack of reported revenue, the company’s near-term guidance would plausibly hinge on fundraising plans, regulatory/clinical milestones, and potential strategic collaborations. Investors should monitor: (1) any announced milestones related to regulatory approvals or clinical data for the sensing platform, (2) capital-raising activities or debt facilities to extend runway, and (3) potential licensing or partnership deals that could begin monetization. The achievability of any target will depend on clinical success, regulatory path timelines, and the company’s ability to secure favorable collaboration terms.